Generic Drug Maker Taro Admits To Price Fixing, Agrees To Pay $205M Criminal Penalty
PHILADELPHIA — Taro Pharmaceuticals U.S.A. Inc. entered into a deferred prosecution agreement (DPA) admitting to engaging in antitrust activities and agreeing to pay a $205.65 million criminal penalty, the U.S. Justice...To view the full article, register now.
Already a subscriber? Click here to view full article